BLAINJECTIONINJECTABLE
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
HADLIMA (adalimumab-bwwd) by Samsung Bioepis is tumor necrosis factor receptor blocking activity [moa]. First approved in 2019.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HADLIMA (adalimumab-BWWD) is a biosimilar monoclonal antibody that blocks tumor necrosis factor (TNF), a key inflammatory cytokine. It is administered by injection and is indicated for TNF-mediated inflammatory conditions. The drug works by binding TNF receptors, reducing inflammatory signaling and immune-driven tissue damage.
$0.014BPart D
PeakHADLIMA is at peak maturity with modest Part D spending; biosimilar programs typically maintain stable sales but face significant competitive pressure requiring specialized market access and payer strategies.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HADLIMA offers exposure to biosimilar commercialization, payer negotiations, and competitive market dynamics in the crowded TNF-blocker space. This role emphasizes market access excellence, managed care strategy, and tactical competitive response rather than clinical innovation or launch execution.
Brand Manager
Worked on HADLIMA at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.